Study of LYL314 in Aggressive Large B-Cell Lymphoma

Inclusion Criteria:

1. Age 18 years or older at time of informed consent

2. Willing and able to provide written informed consent

3. Histologically confirmed aggressive NHL, including the following types defined bythe World Health Organization (WHO 2017):

• DLBCL

• DLBCL arising from follicular lymphoma (transformed FL, tFL)

• Primary mediastinal (thymic) large B-cell lymphoma (PMBCL)

• High-grade large B-cell lymphoma with or without MYC and BCL2 and/or BCL6rearrangement (HGBL)

• Grade 3B follicular lymphoma/Large cell follicular lymphoma (FL3B)

4. Received at least two prior lines of therapy for Cohorts 1, 2, and 4 and one priorline of therapy for Cohort 3. Prior therapy must have included:

• Anti-CD20 monoclonal antibody, and

• An anthracycline containing chemotherapy regimen

• Participants with tFL must have received at least one of their prior lines oftherapy after transformation to DLBCL 4b. Cohort 5 (High-risk first-line) participants must have high-risk largeB-cell lymphoma

5. Relapsed or refractory disease, defined by the following:

• Disease progression after last regimen (including salvage therapy afterautologous stem cell transplantation [ASCT]). In participants who have onlyreceived front-line therapy, progression should be ≤ 12 months of first-linetherapy (applicable for Cohort 3)

• In patients who received one line of therapy, refractory disease is defined asfailure to achieve at least a PR after at least 4 cycles of therapy (applicablefor Cohort 3)

• In patients who received two or more lines of therapy (Cohorts 1, 2, and 4),refractory disease is defined as failure to achieve a CR to last line oftherapy (including CAR T and/or salvage therapy).

6. At least 1 measurable lesion (per Lugano classification). Lesions that have beenpreviously irradiated will be considered measurable only if progression has beendocumented following completion of radiation therapy

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 or ECOG 0 to 2 (Cohort 5)

8. Absolute neutrophil count (ANC) ≥ 1000/uL

9. Platelet count ≥ 50,000/uL

10. Absolute lymphocyte count (ALC) ≥ 200/uL

Other protocol-defined criteria apply.

Exclusion Criteria:

1. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless disease-free for at least 3 years.Participants who have received therapy for a prior malignancy within the prior 3years, e.g., in the adjuvant setting, are not excluded

2. Active central nervous system (CNS) involvement by malignancy on magnetic resonanceimaging (MRI) or by lumbar puncture. Participants with prior evidence of brainmetastasis treated at least 8 weeks prior to enrollment will not be excluded forparticipation if CNS disease is deemed stable at the time of study enrollment

3. History of cardiac lymphoma involvement or Epstein-Barr virus (EBV)+ lymphoma

4. Ongoing or impending oncologic emergency (e.g., tumor mass effect, tumor lysissyndrome, known vascular invasion)

5. Received the following therapies in the specified time frame prior toenrollment/leukapheresis

6. Any systemic therapy within 2 weeks

7. Any systemic inhibitory/stimulatory immune checkpoint molecule therapy within 3half-lives prior to enrollment (e.g., ipilimumab, nivolumab, pembrolizumab,atezolizumab, OX40 agonists, 4-1BB agonists)

8. Fludarabine within 12 weeks

9. Alemtuzumab, bendamustine or antithymocyte globuline (ATG) within 6 months

10. Any T cell engager/bispecific antibody therapy such as CD20/CD3 or CD19/CD3bispecific antibodies within 4 weeks

11. Any experimental therapy within 4 weeks or 5 half-lives (whichever is shorter)

12. Received radiation therapy within 3 weeks prior to enrollment/leukapheresis

13. Experiencing non-hematologic toxicities due to prior therapy. Exceptions include:stable and recovered to grade ≤ 1 or non-clinically significant toxicities such as (1) alopecia, (2) toxicities where Grade 2 is solely defined by participantreceiving hormone replacement therapy for endocrinopathies resulting from previouscheckpoint inhibitor therapy, (3) Grade 2 lymphopenia, and (4) hearing loss or Grade 2 neuropathy associated with prior treatment with taxanes or platinating agents

14. History of allogeneic stem cell or solid organ transplantation

15. Receipt of autologous stem cell transplantation within 6 weeks prior toenrollment/leukapheresis

16. History of prior genetically modified cell therapy other than a product targetingCD19 with an FMC63-based CAR (e.g., axicabtagene ciloleucel (axi-cel),tisagenlecleucel (tisa-cel), or lisocabtagene maraleucel (liso-cel). For all otherCAR T cell therapy treatments, discussion with the Sponsor's Medical Monitor isrequired

17. Primary immunodeficiency

18. History of autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemiclupus) resulting in end organ injury or requiring systemicimmunosuppression/systemic disease modifying agents within the last 2 years.Participants who have other autoimmune condition(s) considered to be associated withunderlying malignancy may be enrolled in the study after discussion with andapproval of the Medical Monitor.

Other protocol-defined criteria apply.